ReviewFrontiers in microbiology2026
A compartment-resolved framework for microbial sulfur-reactive sulfur signaling in diabetic cardiomyopathy: from gut metabolism to cardiac sulfur responses.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM) is an important substrate of diabetes-related heart failure and is increasingly considered within a gut-heart systems framework. Here, we propose a compartment-resolved microbial sulfur-cardiac signaling model rather than a linear pathway in which free gut-derived sulfide species are assumed to reach the myocardium intact. Gut microbes generate sulfide through dissimilatory sulfate reduction, anaerobic sulfite reduction, assimilatory sulfur pathways, and sulfur-amino-acid catabolism, whereas intestinal epithelial cells and liver strongly constrain systemic exposure through mitochondrial sulfide oxidation. Recent work reports that microbial sulfide-associated metabolism can influence enteroendocrine GLP-1 signaling, hepatic PPARα-dependent metabolism, and systemic sulfur handling through intestinal SQOR-dependent pathways; however, none of these studies demonstrates direct sulfur transfer from microbial metabolism to the diabetic heart or establishes a sulfur-specific causal pathway leading to myocardial persulfidation. In parallel, diabetic-heart studies report sulfide-donor-responsive persulfidation candidates including MuRF1 Cys44, SYVN1/Hrd1 Cys115, and SENP1 Cys683, but the evidence is concentrated in an overlapping research program and is methodologically dependent. We therefore separate better-supported local processes, cross-organ supporting evidence, and unresolved DCM-specific links, and outline source-resolved isotope tracing, microbial genetics, host sulfur-enzyme models, and orthogonal site-resolved persulfidation assays needed to test causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.